Bulk Pharmaceutical API Sources for ROZLYTREK

Bulk Pharmaceutical API Sources for ROZLYTREK

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-12678
Debye Scientific Co., Ltd		DA-47850
AbaChemScene		CS-4343
ApexBio Technology		B5859
AbovChem LLC		HY-12678

Bulk Active Pharmaceutical Ingredient (API) Sources for Rozlytrek

Last updated: July 28, 2025

---

Introduction

Rozlytrek (entrectinib) is an oral, selective tyrosine kinase inhibitor approved for treating NTRK gene fusion-positive solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). As a targeted cancer therapy, the quality, purity, and supply chain integrity of its active pharmaceutical ingredient (API) are critical for ensuring efficacy, safety, and regulatory compliance. This article examines the primary sources and considerations for bulk API procurement for Rozlytrek, focusing on global manufacturing capabilities, supply chain dynamics, and quality standards.

---

Overview of Rozlytrek's API: Entrectinib

Chemical Profile:
Entrectinib is a potent inhibitor of ROS1, TRKA/B/C, and ALK kinases, with a molecular weight of approximately 560.7 g/mol. Its synthesis involves complex organic chemistry with multiple steps, ensuring high purity standards requisite for oncologic therapeutics.

Regulatory Environment:
The API manufacturing must align with Good Manufacturing Practices (GMP) outlined by regulatory authorities like the FDA, EMA, and other regional agencies. These standards govern impurity profiles, batch consistency, and documentation to support clinical and commercial supply.

---

Key API Manufacturers and Suppliers for Rozlytrek

1. Established Pharmaceutical Contract Manufacturing Organizations (CMOs)

Major CMOs with extensive experience in complex oncology drug APIs serve as primary sources for entrectinib API:

a. Lonza

• Capabilities: Global leader in custom manufacturing of APIs, including high-potency compounds.
• Compliance: GMP-certified facilities adhering to strict quality controls.
• Supply Chain: Robust global network ensures reliable supply for clinical trials and commercial production.

b. WuXi STA

• Specialty: Expertise in complex organic synthesis, including kinase inhibitors.
• Facilities: Multiple GMP manufacturing sites with scalable capacity.
• Strengths: Proven track record for rapid scale-up and transfer of synthetic processes.

c. Selleck Chemicals / ApexBio

• Position: Suppliers primarily for research-grade API, but some offer GMP-grade APIs for early-phase clinical use.
• Note: Use recommended only for preclinical or investigational applications, not for commercial manufacturing.

d. JHP Pharmaceuticals / Huadong Medicine

• Focus: Especially active in Asian markets, with GMP-certified facilities capable of delivering clinical and commercial APIs.

2. Major Pharmaceutical Companies with In-House API Capabilities

Some pharmaceutical firms develop and manufacture their own APIs to ensure control over quality and supply:

a. Pfizer

• Rationale: Being the initial developer of entrectinib, Pfizer maintains in-house API synthesis facilities to supply clinical batches, moving toward commercial-scale production.

b. Roche / Genentech

• Position: Their focus on targeted oncology therapies includes capabilities for complex kinase inhibitor APIs.

---

Geographic Considerations in API Sourcing

Asia-Pacific Region:
Multiple GMP-compliant API suppliers operate in China, India, and South Korea, offering cost-effective and scalable production options. Key players include WuXi AppTec and H. S. Pharma.

North America and Europe:
Regulatory authorities' stringent standards favor suppliers like Lonza and Pfizer, which maintain facilities in Switzerland, the US, and Germany.

Emerging Markets:
Some emerging suppliers can provide APIs at reduced costs but require rigorous validation to meet international quality standards.

---

Quality and Regulatory Compliance Factors

• GMP Certification:
  All API sources must possess GMP certificates acceptable to the target markets' regulatory agencies.

• Impurity Profile & Stability:
  Suppliers must provide comprehensive data on residual solvents, process impurities, and stability under storage conditions.

• Batch Records & Documentation:
  Traceability from synthesis to delivery ensures compliance with specifications in regulatory submissions.

• Prequalification & Audits:
  Pharmacopeial standards (e.g., USP, EP, JP) and facility audits underpin supply chain reliability.

---

Supply Chain Challenges and Strategies

Supply Disruptions:
Global disruptions due to geopolitical issues, pandemics, or regulatory delays can impact API availability.

Solution Strategies:

• Establish multiple supplier relationships to mitigate risk.
• Engage in early technology transfer and process validation.
• Maintain safety stock levels aligned with demand forecasts.

Cost Implications:
Balancing cost with quality remains critical; sourcing from reputable, compliant suppliers often justifies higher costs through reduced regulatory risk.

---

Emerging Trends in API Sourcing for Oncology Drugs

• Vertical Integration:
  Large pharmaceutical firms increasingly develop in-house manufacturing to streamline supply and control costs.

• Advanced Synthesis Techniques:
  Process innovations reduce impurity formation and enhance yields, expanding supplier options.

• Globalization and Localization:
  Regulatory environments push for localized manufacturing in key markets to reduce lead times.

---

Conclusion

The procurement of high-quality bulk entrectinib API for Rozlytrek hinges on sourcing from GMP-compliant, technologically adept manufacturers with proven expertise in complex kinase inhibitors. Leading global CMOs like Lonza and WuXi STA represent the most reliable sources, complemented by in-house manufacturing capabilities of big pharma players such as Pfizer and Roche. To ensure supply chain robustness, strategic diversification, early engagement, and rigorous quality assurance are advisable.

---

Key Takeaways

• Primary sources for Rozlytrek API include established CMOs with expertise in complex organic synthesis and GMP compliance.
• Asia-Pacific manufacturers offer cost-effective options, but North American and European suppliers provide robust regulatory alignment.
• Quality assurance protocols, including GMP certification and impurity analyses, are non-negotiable for API sourcing.
• Supply chain resilience depends on multi-supplier strategies, early technology transfer, and inventory management.
• Emerging trends emphasize in-house manufacturing and process innovations to maintain consistent supply and compliance.

---

FAQs

1. What are the main considerations when choosing a supplier for entrectinib API?
Quality standards, GMP certification, impurity profile, capacity, regulatory track record, and supply reliability.

2. Can research-grade APIs be used for commercial manufacturing of Rozlytrek?
No. Research-grade APIs lack full GMP compliance and are unsuitable for commercial distribution.

3. Are there regional differences in API manufacturing quality?
Yes. While GMP standards are globally aligned, regulators may scrutinize regional facilities differently. Certification and audit reports are critical.

4. How do supply chain disruptions affect Rozlytrek production?
They can delay drug availability, increase costs, and compromise regulatory compliance. Diversification and safety stock mitigate these risks.

5. What emerging trends impact API sourcing for targeted cancer therapies?
In-house manufacturing, process innovation, globalization, and advanced synthesis methods improve supply security and quality control.

---

References

[1] U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review: Rozlytrek.
[2] EMA. Summary of Product Characteristics: Entrectinib.
[3] Lonza Group AG. API manufacturing capabilities.
[4] WuXi AppTec. Custom API synthesis and manufacturing services.
[5] Pfizer. Technical documentation on entrectinib API production.